TAVR

Transcatheter aortic valve replacement (TAVR) is a key structural heart procedure that has rapidly expanded in the decade since it was first FDA cleared. TAVR has come a paradigm shift in how many aortic stenosis patients are treated, now making up more than 50% of U.S. aortic valve replacements. It is less invasive than open heart surgery and recovery times are greatly reduced. TAVR can also be used in patients who otherwise are too high risk to undergo surgery. TAVR is referred to as transcatheter aortic valve implantation (TAVI) in many placed outside of the U.S. TAVR inspired the growing areas of transcatheter mitral repair or replacement and transcatheter tricuspid valve repair and replacement.

RSS icon

Specialists complete first procedure in historic head-to-head TAVR study

The global trial is designed to compare TAVR systems from Medtronic and Edwards Lifesciences when treating patients with small annuli.

April 13, 2021
Large peridevice leaks after left atrial appendage occlusion (LAAO) are incredibly rare and not associated with a greater risk of adverse outcomes, according to new research published in JACC: Clinical Electrophysiology.[1] Smaller residual links are more common, however, and associated with a risk of thromboembolic and bleeding events.

What TAVR availability has meant for patients with severe aortic stenosis

The impact on patients over the age of 65 has been undeniable. 

April 2, 2021

How heart rhythm issues affect 2-year TAVR, SAVR outcomes

The study’s authors explored data from more than 900 low-risk patients who participated in the PARTNER 3 trial.

March 10, 2021
home rehab

Researchers examine ‘concerning’ out-of-hospital 30-day mortality rate for TAVR patients

Researchers examined data from more than 98,000 patients who underwent transfemoral TAVR from January 2015 to March 2018. 

February 3, 2021
Hypertension patients measured their blood pressure less frequently during the early months of the COVID-19 pandemic, according to new research published in Hypertension. In addition, when those patients did measure their blood pressure, the readings were less healthy than they had been before the pandemic.

TAVR in the time of COVID-19: Providers quickly adapted, delivering ‘excellent’ outcomes

Researchers compared patient outcomes from 2019 with data from the pandemic’s first four months, sharing their findings in the American Journal of Cardiology.  

January 19, 2021
Driven by its strategic goal to advance equity in the U.S. healthcare innovation sector, the American Medical Association (AMA) recently announced an initiative that supports leading industry stakeholders in committing to equitable health innovation opportunities targeted to improving health outcomes in historically marginalized communities. #Healthdisparities 

No reason to quit: TAVR patients can continue anticoagulation therapy throughout procedure

Patients are typically told to put anticoagulation therapy on hold two to four days before they undergo TAVR. This study’s authors aimed to see if this was truly necessary.  

January 19, 2021
With advances and increased experience in the percutaneous coronary intervention (PCI), same-day discharge (SDD) has become increasingly commonplace, but patient selection is key. Antithrombotic therapy may not be necessary for certain transcatheter aortic valve replacement (TAVR) patients, according to a new analysis published in JACC: Cardiovascular Interventions.

CKD patients on dialysis face worse TAVR outcomes, including a higher risk of in-hospital mortality

The authors examined data from more than 42,000 patients who received care from 2012 to 2017. 

January 14, 2021

In-hospital stroke rates higher after TAVR than MitraClip procedures

Post-discharge stroke rates, however, were similar between the two procedures.

January 6, 2021
Displaying 297 - 304 of 340
Design by Adaptive Theme